法律意见书 国浩律师（深圳）事务所 关于 网址/Website: http://www.grandall.com.cn 二〇二五年十月 深圳翰宇药业股份有限公司 二〇二五年第二次临时股东大会 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦 Hongkong·Paris·Madrid·Silicon ...

1、本次股份解除质押基本情况 2、股东股份累计质押情况 证券代码：300199 证券简称：翰宇药业 公告编号：2025-050 深圳翰宇药业股份有限公司 关于控股股东、实际控制人办理部分股票 解除质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份解除质押基本情况 近日，公司接到控股股东、实际控制人曾少贵先生、曾少强先生的通知，曾 少贵先生、曾少强先生办理了部分股票解除质押业务。具体事项如下： | 股东 名称 | 是否为控股 股东或第一 大股东及其 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | 解除 日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 一致行动人 | （股） | （%） | （%） | | | | | 曾少贵 | 是 | | | | | | 深圳担保集团有 | | | | 12,795,875 | 12.99 | 1.45 | 2024/7/24 | 2025/9/30 | 限公司 | | 曾少贵 ...

Group 1 - On September 30, Hanyu Pharmaceutical's stock increased by 1.52%, with a trading volume of 689 million yuan [1] - The financing data shows that on the same day, Hanyu Pharmaceutical had a financing purchase amount of 70.21 million yuan and a financing repayment of 93.34 million yuan, resulting in a net financing outflow of 23.13 million yuan [1] - As of September 30, the total balance of margin trading for Hanyu Pharmaceutical was 1.291 billion yuan, accounting for 6.85% of its market capitalization, which is above the 80th percentile level over the past year [1] Group 2 - As of June 30, the number of shareholders of Hanyu Pharmaceutical was 63,000, an increase of 9.95% compared to the previous period [2] - For the first half of 2025, Hanyu Pharmaceutical achieved an operating income of 549 million yuan, a year-on-year increase of 114.86%, and a net profit attributable to shareholders of 145 million yuan, a year-on-year increase of 1504.30% [2] - Since its A-share listing, Hanyu Pharmaceutical has distributed a total of 417 million yuan in dividends, with no dividends distributed in the last three years [2]

Market Overview - The Shanghai Composite Index rose by 0.90% on September 29, with 26 out of 28 sectors experiencing gains, led by non-bank financials and non-ferrous metals, which increased by 3.84% and 3.78% respectively [1] - The pharmaceutical and biological sector saw a modest increase of 0.17% [1] - The coal and banking sectors were the biggest losers, declining by 0.84% and 0.46% respectively [1] Capital Flow Analysis - The net inflow of capital in the two markets was 9.527 billion yuan, with 13 sectors receiving net inflows [1] - The non-bank financial sector had the highest net inflow of 12.348 billion yuan, corresponding to its 3.84% increase [1] - The non-ferrous metals sector followed with a net inflow of 2.986 billion yuan and a daily increase of 3.78% [1] - Conversely, 18 sectors experienced net outflows, with the electronics sector leading at a net outflow of 2.811 billion yuan, followed by the defense and military sector with 1.882 billion yuan [1] Pharmaceutical and Biological Sector - The pharmaceutical and biological sector had a net outflow of 1.640 billion yuan, with 285 out of 475 stocks in the sector rising, while 169 fell, including 2 hitting the daily limit down [2] - Notable stocks with significant net inflows included Jilin Aodong (10.565 million yuan), Sino Medical (10.067 million yuan), and Mindray Medical (9.186 million yuan) [2] - Major stocks with significant net outflows included Hengrui Medicine (-333.586 million yuan), Guangsheng Tang (-160.353 million yuan), and Hanyu Pharmaceutical (-138.282 million yuan) [4] Top Gainers in Pharmaceutical Sector - Jilin Aodong saw a price increase of 6.69% with a turnover rate of 4.00% and a net inflow of 10.565 million yuan [2] - Sino Medical increased by 4.82% with a turnover rate of 7.00% and a net inflow of 10.067 million yuan [2] - Mindray Medical had a slight increase of 0.19% with a turnover rate of 0.68% and a net inflow of 9.186 million yuan [2] Top Losers in Pharmaceutical Sector - Hengrui Medicine decreased by 1.26% with a turnover rate of 1.02% and a net outflow of 333.586 million yuan [4] - Guangsheng Tang experienced a decline of 6.18% with a turnover rate of 11.07% and a net outflow of 160.353 million yuan [4] - Hanyu Pharmaceutical had a minor increase of 0.24% but still faced a net outflow of 138.282 million yuan [4]

Core Viewpoint - Hanyu Pharmaceutical is launching a private placement to raise up to 968 million yuan to expand its peptide drug production capacity and enhance its market position, following the successful international launch of its core product [1][2]. Group 1: Fundraising and Investment Plans - The company plans to issue shares to no more than 35 specific investors, with the raised funds allocated to various projects, including peptide drug production line expansion and R&D laboratory upgrades [2][3]. - The total investment for the peptide drug production line and green intelligent expansion project is 549 million yuan, with 495 million yuan from the raised funds, accounting for 51.56% of the total [2]. - The company aims to produce an additional 2000 kg of peptide raw materials annually to meet market demand after the completion of the new production line [2]. Group 2: Financial Performance and International Expansion - Hanyu Pharmaceutical has experienced a turnaround, achieving a net profit of 145 million yuan in the first half of 2025, marking a significant recovery from seven consecutive years of losses [6]. - The company's international business has become a key growth driver, with overseas revenue reaching 425 million yuan in the first half of 2025, a year-on-year increase of 272.76%, accounting for 77.4% of total revenue [6]. - The gross profit margin for international business was 66.51%, significantly higher than the domestic margin of 48.61% [6]. Group 3: Product Development and Market Position - Hanyu Pharmaceutical's liraglutide injection received FDA approval in December 2024, becoming the first generic liraglutide drug in the U.S., which has bolstered its international market presence [1][5]. - The company currently has 29 peptide drugs, 9 new drug certificates, and 31 clinical approvals, with products certified by GMP in multiple regions including the U.S., EU, and South Korea [6].

Core Viewpoint - Han Yu Pharmaceutical (300199) announced that neither the company nor its subsidiaries have any external guarantees outside the scope of the consolidated financial statements, and there are no overdue guarantees [1] Group 1 - The company has confirmed the absence of external guarantees outside the consolidated financial statements [1] - There are no overdue guarantees reported by the company or its subsidiaries [1]

Group 1 - The core point of the article highlights the significant share pledges by major shareholders of Hanyu Pharmaceutical, indicating potential liquidity concerns [1] - As of the announcement date, the cumulative pledged shares by Zeng Shaogui amount to approximately 64.49 million shares, representing 65.45% of his holdings [1] - Zeng Shaoqiang has pledged approximately 37.66 million shares, which is 59.64% of his holdings, while Zeng Shaobin has pledged 8.5 million shares, accounting for 39.14% of his holdings [1] Group 2 - For the first half of 2025, Hanyu Pharmaceutical's revenue composition is entirely from the pharmaceutical manufacturing sector, with a 100% contribution [1] - The current market capitalization of Hanyu Pharmaceutical is 18.5 billion yuan [1]

截至公告披露日，公司控股股东、实际控制人所持股份质押情况如下： 证券代码：300199 证券简称：翰宇药业 公告编号：2025-049 深圳翰宇药业股份有限公司 关于控股股东、实际控制人办理部分股票 解除质押业务的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，公司接到控股股东、实际控制人曾少贵先生、曾少强先生、曾少彬先 生的通知，曾少贵先生、曾少强先生、曾少彬先生办理了部分股票解除质押业务。 具体事项如下： | 股东 | 是否为控股 股东或第一 | 本次解除质 | 占其所持 | 占公司总股 | | 解除 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 大股东及其 | 押股份数量 | 股份比例 （%） | 本比例（%） | 起始日 | 日期 | 质权人 | | | 一致行动人 | （股） | | | | | | | 曾少贵 | 是 | 4,200,000 | 4.26% | 0.48% | 2023/07/27 | 2025/9/26 | 深圳市高新投保 | | | | | ...

Core Viewpoint - The announcement details the partial stock pledge releases by the controlling shareholders of Hanyu Pharmaceutical, indicating a potential shift in their investment strategy and confidence in the company's future [1] Summary by Relevant Sections Shareholder Actions - Mr. Zeng Shaogui released a pledge of 18.99% of his shares, totaling 18.70 million shares, which represents 2.12% of the company's total share capital [1] - Mr. Zeng Shaoqiang released a pledge of 23.14% of his shares, totaling 14.61 million shares, which represents 1.65% of the company's total share capital [1] - Mr. Zeng Shaoqiang also released an additional pledge of 9.88% of his shares, totaling 6.24 million shares, which represents 0.71% of the company's total share capital [1] - Mr. Zeng Shaobin released a pledge of 13.81% of his shares, totaling 3 million shares, which represents 0.34% of the company's total share capital [1] - In total, 55.10 million shares were released from pledge, accounting for 6.25% of the company's total share capital [1]

证券代码：300199 证券简称：翰宇药业 公告编号：2025-048 深圳翰宇药业股份有限公司 关于2025年度向金融机构申请综合授信 及担保额度的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别风险提示： 截至本公告披露日，公司及控股子公司累计对外提供担保总额占最近一期经 审计净资产133.93%、对资产负债率超过70%的单位担保金额占公司最近一期经 审计净资产69.98%；公司及子公司无对合并报表范围外的对外担保事项，也不存 在逾期担保。敬请广大投资者注意风险。 一、授信及担保审议程序 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于2025 年2月28日召开第六届董事会第二次会议、2025年3月17日召开2025年第一次临时 股东大会，审议通过了《关于2025年度申请综合授信及担保额度的议案》，同意 公司及子公司2025年度向金融机构申请综合授信及担保额度总计不超过3.5亿元。 其中：公司为子公司、子公司之间提供综合授信及担保额度5,000万元；子公司 为本公司提供综合授信及担保额度不超过30,000万元。该授信自2025年3 ...